GlassScriptPhysician profile
Michael John Halvonik
NPI 1538249404
$9,984.59
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $1,401 · 2021: $1,551 · 2022: $1,945 · 2023: $2,197 · 2024: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,890.80 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,164.74 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,134.11 | 2019-2024 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $582.65 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $438.31 | 2020-2024 | Glassia, Cuvitru |
| Grifols USA, LLC | $418.56 | 2019-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $373.66 | 2019-2024 | Dupixent |
| Amgen INC. | $263.91 | 2022-2024 | Tezspire |
| Inogen, INC. | $191.00 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Mylan Specialty L.P. | $168.04 | 2020-2024 | Yupelri |
| Philips North America LLC | $142.68 | 2019-2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $139.98 | 2019-2023 | Xolair |
| Electromed, INC. | $139.55 | 2019-2024 | Smartvest |
| Sunovion Pharmaceuticals INC. | $130.20 | 2019-2021 | |
| Insmed, INC. | $114.91 | 2019-2023 | Arikayce |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $79.68 | 2022-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $74.21 | 2020-2024 | Zerbaxa, Recarbrio |
| Mallinckrodt Hospital Products INC. | $72.95 | 2020-2023 | Acthar |
| Covis Pharma Gmbh | $58.16 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $55.70 | 2019-2023 | |
| Pfizer INC. | $39.96 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $39.51 | 2021-2023 | Airduo Digihaler |
| Actelion Pharmaceuticals US, INC. | $34.64 | 2024 | Opsumit |
| Nabriva Therapeutics, Plc | $30.09 | 2022 | |
| Paratek Pharmaceuticals, INC. | $26.70 | 2020 | |
| Circassia INC. | $26.19 | 2019 | |
| Baxter Healthcare | $25.27 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $24.09 | 2021 | |
| Astellas Pharma US INC | $23.36 | 2020 | |
| Fisher & Paykel Healthcare INC | $20.34 | 2019 | |
| Mayne Pharma Commercial LLC | $18.46 | 2020 | |
| Shire North American Group INC | $15.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.80 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Halvonik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.